Allergy Diagnostics and Therapeutics Market Outlook 2031
The global allergy diagnostics and therapeutics market size was valued at USD 7.29 Billion in 2022 and is anticipated to reach USD 18.80 Billion by 2031, expanding at a CAGR of 11.1% during the forecast period, 2023 – 2031. The growth of the market is attributed to increasing allergic disease cases, as well as a significant requirement for in vitro diagnostic blood tests.
Allergy diagnostics refers to various types of tests that can be used to detect if a person is more likely to develop or has developed an allergy or allergies. On the other hand, therapeutics are the types of remediation that people take to avoid or decrease the effects of various types of health problems.
According to the World Health Organization (WHO), about 40 million cases of inhalation allergies were reported in the US in 2012. The enforced lockdowns and imposed limits by regulatory bodies in the wake of the recent COVID-19 outbreak, numerous industries' operations have either been temporarily halted or are operating with reduced personnel. The worldwide allergy diagnostics and therapeutics market is no exception, and this factor has negatively impacted the industry growth.
During the forecast period, the introduction of technologically enhanced diagnostic and therapeutic products that provide extremely sensitive and accurate results is expected to positively impact the global market. In 2018, the inhaled allergen type category held a prominent market share, and this trend is expected to continue in the projected timeline.
This increase can be ascribed to rising number of people suffering from respiratory allergies. According to the data published by American Academy of Allergy Asthma and Immunology (AAAAI) in 2012, over 7.8 million children globally suffer from respiratory allergies.
Allergy Diagnostics and Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of allergic conditions coupled with adoption of immunoassay as diagnostic test is projected to drive the market growth during the forecast period.
- Changing lifestyles, rising levels of indoor and outdoor pollution, poor eating habits, and rapid urbanization are contributing to the increase in allergic disease cases.
- Rising greenhouse gas (GHG) concentrations is expected to increase the prevalence of pollen-induced respiratory disease, which is anticipated to spur the market expansion during the forecast period.
- The introduction of technologically advanced products, such as the MeDALL allergen-chip for allergy detection is estimated to propel the market expansion in the coming years.
Scope of Allergy Diagnostics and Therapeutics Market Report
The report on the global allergy diagnostics and therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Allergy Diagnostics and Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Instruments, Consumables, and Services), Allergen Types (Food, Inhaled, Drug, and Others), End Uses (Diagnostic Laboratories, Hospitals, and Academic Research Institutes), Diagnostic Tests (In vivo Test
[Skin Prick Test, Intradermal Test, and Patch Test], and In vitro Test), and Drug Classes (Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, and Immunotherapy)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
bioMerieux, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics, Hitachi Chemical Diagnostics, Stallergenes Greer, Siemens Healthcare, Lincoln Diagnostics, Hycor Biomedical, HOB Biotech Group, and Alcon Laboratories.
Allergy Diagnostics and Therapeutics Market Segment Insights
Consumables segment is projected to account for a key market share
Based on products, the market is divided into instruments, consumables, and services. The consumables segment is expected to account for a key share of the market during the forecast period owing to technological advancements, such as allergen microarray kits that are more sensitive and provide patients effective profiling and monitoring.
Furthermore, the introduction of products such as MeDALL allergen-chip, which is associated with increased sensitivity specificity and faster diagnosis, is expected to support the market segment growth.
In vitro segment is expected to grow at a rapid pace
On the basis of diagnostic tests, the allergy diagnostics and therapeutics market is bifurcated into in vivo and in vitro test. The in vivo segment is further divided into skin prick test, intradermal test, and patch test.
The skin prick sub-segment is expected to account for a key market share owing to to greater adoption of this test by healthcare professionals and patients.
This is owing to the increasing use of skin prick tests for food allergy identification and specific IgE-mediated allergy testing. However, the in vitro segment is anticipated to expand at a rapid pace during the forecast period owing to growing demand for less invasive diagnostic methods, laboratory automation, and highly sensitive and accurate results. Companies are focusing on providing allergy-specific solutions and accurate result-oriented devices to expand their market share.
Inhaled segment is anticipated to register a substantial CAGR
In terms of allergen types, the market is segregated into food, inhaled, drug, and others. The inhaled segment is expected to account for a significant market share owing to increasing incidence of respiratory allergies and asthma across the globe.
Rising demand for allergy testing and the introduction of specific allergens for allergy detection are expected to contribute to the high CAGR of this market segment. However, the drug segment is anticipated to expand at a rapid pace during the forecast period. In terms of revenue share, food segment accounted for second-largest market in 2020 and this trend is expected to continue in the projected timeline.
This sort of allergy disorder is more common in children. Food allergies are twice as common in youngsters as they are in adults, according to figures published by the US National Institute of Health (NIH).
The hospital segment is expected to grow at a rapid pace
Based on end uses, the allergy diagnostics and therapeutics market is divided into diagnostic laboratories, hospitals, and academic research institutes. The diagnostic laboratories segment is expected to account for a considerable market share during the forecast period owing to the widespread use of immunoassay tests in allergy diagnosis.
Ongoing advancements in screening techniques that allow accurate disease diagnosis and stratification for appropriate treatment are expected to drive the segment growth. However, the hospital segment is anticipated to expand at a rapid pace during the forecast period owing to the government support and rising investment in the healthcare infrastructure.
Immunotherapy segment is expected to grow at a rapid pace
On the basis of drug classes, the market is classified as antihistamines, decongestants, corticosteroids, mast cell stabilizers, leukotriene inhibitors, nasal anticholinergics, immunomodulators, auto injectable epinephrine, and immunotherapy.
The immunotherapy segment is expected to account for a large market share during the forecast period owing to rising demand for sublingual vaccinations, a large medication pipeline, increasing number of clinical studies of monoclonal antibodies for the treatment of allergic diseases, and growing patient awareness.
The antihistamines segment dominated the market share in 2018, owing to their numerous benefits and applications in the treatment of allergic illnesses. According to the American Academy of Allergy Asthma & Immunology (AAAAI), allergic rhinitis affects 10% to 30% of the global population, contributing to the adoption of allergy treatments.
In terms of regions, the allergy diagnostics and therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period.
The regional market growth is attributed to rapidly improving healthcare infrastructure, unmet clinical requirements, and increasing demand for minimally invasive diagnostic tools.
In terms of revenue, North America led the global market in 2018 due to a high prevalence of respiratory allergic disorders, rising awareness of allergy diagnostics, and the adoption of in vitro blood tests.
Factors such as presence of a developed pharmaceutical industry and rising demand for therapeutics are expected to help Europe to become a prominent market in the projected timeline. The regional market growth is attributed to growing geriatric population and increasing prevalence of allergic conditions.
The global allergy diagnostics and therapeutics market has been segmented on the basis of
- Diagnostic Laboratories
- Academic Research Institutes
- In vivo Test
- Skin Prick Test
- Intradermal Test
- Patch Test
- In vitro Test
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Nasal Anticholinergics
- Auto injectable Epinephrine
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Key players competing in the allergy diagnostics and therapeutics market include bioMerieux, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics, Hitachi Chemical Diagnostics, Stallergenes Greer, Siemens Healthcare, Lincoln Diagnostics, Hycor Biomedical, HOB Biotech Group, and Alcon Laboratories.
Companies are actively involved in new product launches, strategic collaborations, acquisitions, and technological improvements to achieve maximum market share in a highly competitive market.
- In October 2017, Stallergenes Greer purchased Medic Savoure Ltd., bolstering its position in the allergy immunotherapy industry in Canada.
- In July 2016, Novartis AG got FDA approval for the use of its medicine, Xolair, in the treatment of juvenile allergic asthma, which helped to broaden the company's product line.